New Horizons in the Treatment and

Management of Rheumatoid Arthritis

New Horizons in the Treatment and Management of Rheumatoid Arthritis is a 4-part series that will
provide attendees with the latest information in RA Management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 4 or in order.

These are archives of live webinars held between January 20, 2017 and March 10, 2017.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.

This series is supported by an educational grant from Lilly, USA LLC

 Description:  Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. With so many new options becoming available for clinicians, it is critical that rheumatologists, primary care physicians, managed care medical directors, payers, case managers, nurses, and other healthcare professionals (HCPs) are updated on these emerging options and guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
 



 
Exploring Mechanisms of Action in JAK Inhibitors and the Role of the JAK/STAT Pathway in the Pathogenesis of RA
  • Explore the mechanism of action in janus kinase (JAK) inhibitors
  • Review how JAK inhibition differs from other Rheumatoid Arthritis (RA) therapies and how the mechanism of action in JAK inhibitors can provide advantages for patients with RA
  • Discuss the role of the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in the pathogenesis of RA
  • Explain the pharmacokinetic and pharmacodynamic differences across the JAK inhibitors in patients with RA
  • Examine the difference between small molecules and biologics in the treatment of RA
Physician, Nursing and CMCN credits valid to April 30, 2019
 
Where Do JAK inhibitors Fit in the Emerging Treatment Paradigm in the Management of RA
  • Review efficacy and safety data and updates of new and emerging JAK inhibitors in the management of RA for achieving treatment goals
  • Examine the place in therapy for JAK inhibitors based on established RA guidelines, available clinical data and ongoing clinical trials
  • Implement tailored treatment regimens for moderate-to-severely active RA based on repeated assessment of disease activity, functional status, treatment response, and other patient-specific risks
  • Discuss recent clinical trial data of emerging JAK inhibitors in patients with rheumatoid arthritis
Physician, Nursing and CMCN credits valid to April 30, 2019
 

How to Improve Patient Adherence and Safety in RA: Strategies to Monitor and Manage Adverse Events Associated with Emerging JAK Inhibitors

  • Review adverse events associated with JAK inhibitors in the management of RA
  • Implement strategies for monitoring and managing those adverse events and tools and guidelines HCPs and patients can use to improve quality of life while taking JAK inhibitors
  • Discuss barriers to treatment in RA management as it pertains to JAK inhibitors and review how clinicians (rheumatologists, primary care physicians), managed care physicians and payers can overcome those challenges
Physician, Nursing and CMCN credits valid to April 30, 2019
 

What Managed Care Needs to Know About JAK Inhibitors in the Evolving Management of RA

  • Discuss methods to enable optimal cost management of both current and emerging JAK inhibitors to be realized by multiple RA stakeholders including managed care organizations
  • Analyze strategies used by managed care organizations to facilitate high quality care for members with RA, and how JAK inhibitors can affect those strategies
  • Discuss how emerging therapies that are currently undergoing regulatory review and late stage clinical trials will affect managed care professionals in the RA arena if they become available
Physician, Nursing and CMCN credits valid to April 30, 2019